The Math Shows IBB Can Go To $356

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Nasdaq Biotechnology ETF ( IBB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $356.49 per unit.

10 ETFs With Most Upside To Analyst Targets »

With IBB trading at a recent price near $286.51 per unit, that means that analysts see 24.43% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IBB's underlying holdings with notable upside to their analyst target prices are Affimed N.V. ( AFMD), Dicerna Pharmaceuticals Inc ( DRNA), and Egalet Corp ( EGLT). Although AFMD has traded at a recent price of $2.30/share, the average analyst target is 231.52% higher at $7.62/share. Similarly, DRNA has 119.74% upside from the recent share price of $3.47 if the average analyst target price of $7.62/share is reached, and analysts on average are expecting EGLT to reach a target price of $14.88/share, which is 85.24% above the recent price of $8.03. Below is a twelve month price history chart comparing the stock performance of AFMD, DRNA, and EGLT:

AFMD, DRNA, and EGLT Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
iShares Nasdaq Biotechnology ETF IBB $286.51 $356.49 24.43%
Affimed N.V. AFMD $2.30 $7.62 231.52%
Dicerna Pharmaceuticals Inc DRNA $3.47 $7.62 119.74%
Egalet Corp EGLT $8.03 $14.88 85.24%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Indices Don't Have Much in Common

Trader's Daily Notebook: 3 ETFs With Healthy Setups

Trader's Daily Notebook: Keeping a Short Leash